Duvelisib - CAS 1201438-56-3
Catalog number: B0084-462545
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C22H17ClN6O
Molecular Weight:
416.869
COA:
Inquire
Targets:
PI3K
Description:
Duvelisib, also known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, PI3K delta/gamma inhibitor IPI 145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-462545 100 mg $228 In stock
Bulk Inquiry
Appearance:
white solid powder
Synonyms:
IPI145; IPI 145; IPI-145. INK-1197; INK 1197; INK1197; Duvelisib.
MSDS:
Inquire
Application:
For research used only
InChIKey:
SJVQHLPISAIATJ-ZDUSSCGKSA-N
InChI:
InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
Canonical SMILES:
CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
Current Developer:
Infinity Pharmaceuticals, Inc. and Intellikine
1.The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K1,2, Peluso M3, Fu M2, Rosin NY2, Burger JA2, Wierda WG2, Keating MJ2, Faia K3, O'Brien S2, Kutok JL3, Gandhi V1,2. Leukemia. 2015 Sep;29(9):1811-22. doi: 10.1038/leu.2015.105. Epub 2015 Apr 28.
The functional relevance of the B-cell receptor (BCR) and the evolution of protein kinases as therapeutic targets have recently shifted the paradigm for treatment of B-cell malignancies. Inhibition of p110δ with idelalisib has shown clinical activity in chronic lymphocytic leukemia (CLL). The dynamic interplay of isoforms p110δ and p110γ in leukocytes support the hypothesis that dual blockade may provide a therapeutic benefit. IPI-145, an oral inhibitor of p110δ and p110γ isoforms, sensitizes BCR-stimulated and/or stromal co-cultured primary CLL cells to apoptosis (median 20%, n=57; P<0.0001) including samples with poor prognostic markers, unmutated IgVH (n=28) and prior treatment (n=15; P<0.0001). IPI-145 potently inhibits the CD40L/IL-2/IL-10 induced proliferation of CLL cells with an IC50 in sub-nanomolar range. A corresponding dose-responsive inhibition of pAKT(Ser473) is observed with an IC50 of 0.36 nM. IPI-145 diminishes the BCR-induced chemokines CCL3 and CCL4 secretion to 17% and 37%, respectively.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products


CAS 1246560-33-7 VS-5584

VS-5584
(CAS: 1246560-33-7)

VS-5584 is a pan-PI3K/mTOR kinase inhibitor with IC50s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 s...

CAS 1254036-66-2 GSK2292767

GSK2292767
(CAS: 1254036-66-2)

GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials....

CAS 957054-30-7 GDC0941

GDC0941
(CAS: 957054-30-7)

GDC-0941 is a potent pan inhibitor of class I catalytic subunits of PI3K that inhibits p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM.

SAR-405
(CAS: 1523406-39-4)

SAR-405 is a potent and selective inhibitor of phosphoinositide 3-kinase (PI3K) class III isoform Vps34 (IC50= 1.2 nM, Kd= 1.5 nM) without disrupting other PI3K...

CAS 2001571-40-8 eCF309

eCF309
(CAS: 2001571-40-8)

eCF309 is a potent and cell-permeable inhibitor of mTOR signaling (IC50 value 10 - 15 nM in vitro and in vivo) that exhibits >60-fold selectivity over PI3Ks. It...

CAS 1276553-09-3 PF-4989216

PF-4989216
(CAS: 1276553-09-3)

PF-4989216 is a novel potent and selective PI3K inhibitor. PF-4989216 inhibits the phosphorylation of PI3K downstream molecules and subsequently leads to inhib...

CAS 1252594-99-2 ETP-46321

ETP-46321
(CAS: 1252594-99-2)

ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...

CAS 934389-88-5 LY 294002 hydrochloride

LY 294002 hydrochloride
(CAS: 934389-88-5)

LY 294002 hydrochloride is a PI 3-kinase inhibitor with IC50 values of 0.31μM for PI 3-Kβ, 0.73μM for PI 3-Kα, 1.06μM for PI 3-Kδ and 6.60μM for PI 3-Kγ. It can...

Chemical Structure

CAS 1201438-56-3 Duvelisib

Quick Inquiry

Verification code

Featured Items